CytoSorbents Corp Announces 1-for-20 Reverse Stock Split

What Happened
CytoSorbents Corporation announced a one-for-twenty (1:20) reverse stock split of its common stock, effective at 12:01 a.m. ET on September 8, 2026. The split was approved by shareholders at the August 13, 2026 annual meeting and executed by a Certificate of Amendment filed with the Delaware Secretary of State on September 3, 2026. The company reported 63,022,020 shares outstanding prior to the split, which results in 3,151,101 shares outstanding after the reverse split.

Key Details

• Reverse ratio: 1-for-20, effective September 8, 2026 at 12:01 a.m. ET.
• Outstanding shares before/after: 63,022,020 before; 3,151,101 after.
• Options/warrants: outstanding options and warrants were proportionately reduced and their exercise prices adjusted automatically.
• Administrative details: No fractional shares were issued; fractional entitlements were rounded up to the nearest whole share. Equiniti Trust Company, LLC is acting as exchange agent. Trading on Nasdaq will continue on a split-adjusted basis. New CUSIP: 23283X305.

Why It Matters
A reverse stock split reduces the number of shares outstanding and increases the per-share price proportionally; it does not change the company’s market value, authorized share count, or the economic ownership of shareholders. For investors, the most immediate effects are a higher reported per-share price and adjusted share counts in brokerage accounts; options and warrants will reflect the new ratio and exercise prices automatically. Shareholders holding stock through a broker (street name) are not required to take action, and the company has provided an exchange agent to handle any record-holder issues.